## CARENET

*Objective*

The objective of the CARENET Trial is to evaluate the periprocedural safety and efficacy of CGuard™ system in the treatment of carotid lesions in consecutive patients suitable for carotid artery stenting (CAS).

*Study design*
Prospective, multi-center, international, open label, single arm, non-randomized clinical trial. 30 consecutive patients will be enrolled in a total of up to 8 experienced centers including Germany, Poland and Belgium. Patient population will include neurologically symptomatic and asymptomatic patients who require carotid artery revascularization and are suitable for carotid artery stenting; symptomatic patients (with history of a transient ischemic attack, stroke or amaurosis fugax within the last 6 months on the ipsilateral side of the stenosis) with carotid stenosis ≥50% as diagnosed by angiography using NASCET methodology; and asymptomatic patients with carotid stenosis ≥80% as diagnosed by angiography using NASCET methodology. Enrollment has begun. The primary endpoint is 30 day MACE (death, stroke, MI).